Rhumbline Advisers Cellectis S.A. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Cellectis S.A. stock. As of the latest transaction made, Rhumbline Advisers holds 1,905 shares of CLLS stock, worth $5,067. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,905
Previous 2,115
9.93%
Holding current value
$5,067
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CLLS
# of Institutions
26Shares Held
13.2MCall Options Held
0Put Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$12.5 Million0.33% of portfolio
-
B Group, Inc. Dallas, TX3.26MShares$8.66 Million3.82% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.18MShares$8.46 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$3.83 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$603,4870.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $121M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...